Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases
CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.